AstraZeneca Launches $600M China Drug Americans Flew to Buy

AstraZeneca said on 22 October 2026 that Zegfrovy (sunvozertinib), a lung-cancer pill developed by Shanghai-based Dizal Pharmaceutical, is now available in the US. Two days earlier, a KFF Health News report published by The Washington Post described Americans travelling to China to obtain the drug, which the FDA licensed in July 2025 but which “wasn’t yet on the U.S. market as of this week.”

AstraZeneca paid Dizal $600 million upfront for worldwide rights, with up to $900 million more in milestones plus royalties, according to its own release. The deal sits inside a wider shift: companies in the greater China region signed licensing deals worth $137.7 billion in 2025, Reuters reported, citing Pharmcube data.

Business Pill · ROYALTIES

A short Business Engineer explainer on royalties: paying each time you use someone else’s work. It teaches the general idea only and says nothing about AstraZeneca, Dizal or any company in this piece.

What Happened

The KFF Health News report follows Max Doppelt, a New York computer engineer, who sought the drug for his mother. When she did not qualify for the relevant clinical trials, a doctor told him: “Too bad she’s not Chinese,” adding: “She could go to a pharmacy in China and buy it.”

• The trip. “So Max flew to Shanghai, returning with 26 boxes of sunvozertinib in his luggage. The drugs cost about $10,000, he said.”
• Others. He said he knows of at least 30 Americans who have made the trip, the report says.
• The approvals. The drug “gained approval in China in 2023”. The FDA granted accelerated approval, and AstraZeneca’s release notes that “Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.”
• The launch. AstraZeneca’s 1 September release said it “will launch in the US during the fourth quarter of 2026”. On 22 October it announced “the US availability of ZEGFROVY”, through a specialty distribution and pharmacy network.

The drug is sunvozertinib, sold as Zegfrovy. About 15 months passed between the FDA licence and the US launch, by our arithmetic; VnExpress puts it at “more than 15 months”.

What AstraZeneca Paid

AstraZeneca “will make an upfront payment of $600m to Dizal together with additional payments of up to $900m upon achievement of specific development, regulatory and sales-related milestones. Additionally, Dizal will receive tiered royalties on the global sales of ZEGFROVY,” its 1 September release says. Through the agreement, it “has acquired worldwide rights to develop and commercialize ZEGFROVY.”

That upfront is about 7.7 times the average upfront in China out-licensing deals in early 2026, and about 15 times the $40 million AstraZeneca agreed to pay insitro this month, by our arithmetic. The table sets the figures side by side.

The Pharmcube averages cover licensing deals signed by companies in the greater China region; the 2026 figure is as of Reuters’ 13 February report. The insitro deal is a research collaboration, not a licence for an approved drug.

China’s Place in Drug Development

China has become “a biotech powerhouse, accounting for as much as 46 percent of new drugs tested around the world in 2025,” the KFF Health News report says. “U.S. pharmaceutical companies are testing new therapies there and signing billion-dollar contracts with Chinese firms to develop and market their drugs.”

• Deal value. Licensing deals signed by companies in the greater China region “rose nearly tenfold last year from 2021 to an unprecedented $137.7 billion, according to data provider Pharmcube,” Reuters reported on 13 February. It counted 186 such deals in 2025.
• Big deals. Reuters named AstraZeneca’s experimental weight-loss drug deal worth up to $18.5 billion with CSPC Pharmaceutical Group and AbbVie’s up to $5.6 billion licensing deal with RemeGen.
• Why buyers come. “Many MNCs (multinationals) are considering China as an integral part of their global R&D infrastructure,” Macquarie Capital analysts wrote, as quoted by Reuters. “This is especially true as some firms cut costs whilst facing looming patent cliffs.”
• Early-stage share. VnExpress, citing a study in the Journal of the American Medical Association, reports that China’s share of early-stage drug development programmes worldwide rose from 8% in 2015 to 32% in 2024, while the US share fell from 48% to 37%.

Washington’s Two Responses

The report describes two US policy moves pulling in different directions. “The Trump administration in June kicked off Operation TrialBlazer, aimed at speeding up some FDA regulatory processes to lure back more clinical trials.” Heidi Overton, nominated to lead the FDA, said at her 24 September confirmation hearing that the movement of trials overseas “should give pause to every American and those who serve on their behalf.”

In Congress, Rep. John Moolenaar “in June co-sponsored legislation with Rep. Debbie Dingell (D-Michigan) requiring all U.S. pharmaceutical deals with Chinese companies to be cleared by the Treasury Department,” the report says. Peter Kolchinsky of RA Capital Management, which has Chinese investments in its biotech portfolio, disagreed: “We may be adversaries in many areas, but we’re not competing with them to cure cancer. We are collaborating with them to cure cancer.”

Connecting the Coverage

AstraZeneca has announced other outside partnerships this month. In our insitro piece, insitro said on 15 October it would receive $40 million upfront and up to about $1.46 billion in milestones from AstraZeneca for a research collaboration. In our Oracle piece, AstraZeneca and Oracle announced on 20 October a non-binding agreement to explore how AI and real-world data can help clinicians find patients for clinical trials.

The Treasury question is not limited to drugs. In our Treasury piece, the US Treasury on 22 October proposed a rule that would bar US investors from backing companies in China that develop AI systems. Our Treasury piece describes that rule as covering AI developers; the Moolenaar-Dingell bill, as KFF Health News describes it, would bring drug deals under Treasury clearance.

An X post relaying the KFF Health News story called it US pharma’s “DeepSeek moment”; the report itself does not use the phrase.

The Structural Read

As we read it, the story has two clocks. The drug was approved in China in 2023 and licensed by the FDA in July 2025, but US availability came only after AstraZeneca completed its licence on 1 September and announced the launch on 22 October.

As we read it, the licensing figures Reuters reported describe a market in which global drugmakers buy China-developed assets at scale, with $137.7 billion of deals signed by greater-China companies in 2025, per Pharmcube.

As we read it, Washington’s two responses in the report point different ways: TrialBlazer aims to speed up FDA processes, while the Moolenaar-Dingell bill would require Treasury clearance of US pharmaceutical deals with Chinese companies.

Three Implications

FOR BIG PHARMA BUYERS AstraZeneca’s release lists $600 million upfront, up to $900 million in milestones and tiered royalties on global sales for worldwide rights to a drug approved in China in 2023.

FOR CHINESE DEVELOPERS Reuters, citing Pharmcube, put the average upfront fee in China out-licensing deals at $77.7 million in early 2026, against $38.8 million in 2025.

FOR US POLICY KFF Health News reports that a House bill would require Treasury clearance for all US pharmaceutical deals with Chinese companies, while the FDA’s TrialBlazer programme aims to speed up trials.

The Business Engineer Lens

This story maps onto the Business Engineer framework Inside Anthropic’s Permission Layer.

The framework argues: “As the U.S. and China continue to disentangle across critical technologies, AI becomes one of the central arenas through which that broader geopolitical realignment plays out.”

As we read it, biotech shows the same tension outside AI: US buyers license China-developed drugs while Congress weighs Treasury clearance of those deals. The framework was published in June 2026 about AI governance and does not discuss pharmaceuticals.

What Is Not Established

Neither AstraZeneca release we read gives the US price of Zegfrovy. The count of at least 30 Americans who travelled for the drug is Max Doppelt’s, as reported. Reuters’ deal figures date from 13 February 2026. AstraZeneca has not said whether the reports affected its launch timing; its spokesperson said the company had been working to bring the drug to US patients as quickly as possible, VnExpress reports, citing the South China Morning Post.

The Bottom Line

AstraZeneca announced US availability of a China-developed lung-cancer pill on 22 October 2026, about 15 months after the FDA licensed it, having paid Dizal $600 million upfront and up to $900 million in milestones for worldwide rights. Companies in the greater China region signed $137.7 billion of licensing deals in 2025, according to Pharmcube data cited by Reuters.